SomnoMed Limited (ASX:SOM)
Australia · Delayed Price · Currency is AUD 0.4600
-0.0200 (-4.17%)
Jul 17, 2026, 12:01 PM AEST
SomnoMed Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, SomnoMed stock has a consensus rating of "Strong Buy" and an average price target of $1.03. The average 1-year stock price forecast is 123.91% higher than the current stock price, while the lowest is $0.99 (+115.22%) and the highest is $1.09 (+136.96%).
Price Target: $1.03 (+123.91%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Apr 16, 2026.
Analyst Ratings
The average analyst rating for SomnoMed stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Dec '25 | Feb '26 | Mar '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $1.00 | Buy | Maintains | $1.00 | +117.39% | Apr 16, 2026 |
| Morgans | Morgans | Buy Maintains $0.99 | Buy | Maintains | $0.99 | +115.22% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
122.63M
from 111.49M
Increased by 9.99%
Revenue Next Year
133.69M
from 122.63M
Increased by 9.02%
EPS This Year
0.01
from -0.01
EPS Next Year
0.03
from 0.01
Increased by 94.85%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.